Journal Publication of International Research for Engineering and Management (JOIREM)
Volume: 05 Issue: 06 | June-2025

AI-Driven Early Detection of Rare Genetic Disorders in Neonates

Dr. Sridhar Reddy

Osmania University

Abstract- Early detection of rare genetic disorders in neonates is crucial for timely intervention and improved clinical outcomes. Traditional diagnostic methods face limitations including lengthy turnaround times, fragmented data, and reliance on clinician expertise, which often delay diagnosis. Artificial Intelligence (AI), through advanced machine learning and deep learning algorithms, offers a transformative approach by rapidly analyzing complex genomic, phenotypic, and clinical data to identify patterns indicative of rare diseases. Integrating AI with neonatal screening programs enhances diagnostic accuracy, reduces the diagnostic odyssey, and enables personalized care. Despite challenges such as data privacy, algorithmic bias, and ethical considerations, ongoing advancements in AI and collaborative efforts promise to revolutionize neonatal care. This article explores the role of AI in genomic and phenotypic data analysis, real-world applications, benefits, challenges, and future prospects of AI-driven early detection of rare genetic disorders in neonates.

Keywords: Artificial Intelligence, Early Detection, Rare Genetic Disorders, Neonates, Genomic Data Analysis.

1. Introduction

The early detection of rare genetic disorders in neonates is a critical area of focus in modern pediatric medicine. These disorders, while individually rare, collectively impact a significant number of infants globally and often result in life-altering consequences if left undiagnosed or untreated. Timely diagnosis can mean the difference between a normal developmental trajectory and lifelong disability or even death. However, the current standard of care often faces significant limitations due to the complexity, variability, and low incidence rates of many rare conditions, making early identification a persistent challenge.

In recent years, advances in Artificial Intelligence (AI) have opened promising new avenues for enhancing neonatal diagnostics. AI technologies, especially those leveraging machine learning and deep learning, offer powerful tools for processing vast datasets derived from genomic sequencing, electronic health records (EHRs), and phenotypic observations. These systems can detect patterns and anomalies that are often imperceptible to human clinicians, enabling faster and more accurate identification of rare disorders. Moreover, AI's ability to integrate and analyze diverse types of data holds potential for a paradigm shift in how early diagnostics are approached in neonatology [1-6].

The application of AI in this domain is not merely a technological evolution—it represents a fundamental enhancement of clinical capability. By enabling the rapid screening of newborns at scale and prioritizing high-risk cases for further genetic analysis, AI can significantly reduce the time from symptom onset to diagnosis, often referred to as the "diagnostic odyssey." This is especially valuable in time-sensitive cases where early intervention can dramatically alter clinical outcomes.

This article aims to explore the integration of AI into the early detection framework for rare genetic disorders in neonates. It will provide an overview of the medical background of these conditions, the current limitations of conventional diagnostic approaches, and how AI technologies can be employed to improve early detection. We will also examine real-world applications and case studies, evaluate the benefits and risks associated with this approach, and discuss ethical and logistical challenges. Finally, we will offer a forward-looking perspective on the role AI is likely to play in shaping the future of neonatal care.

2. Understanding Rare Genetic Disorders in Neonates

Rare genetic disorders in neonates encompass a wide spectrum of inherited conditions that manifest early in life, often within the first few days or months after birth. While individually uncommon, these disorders collectively affect millions of newborns each year worldwide. Examples include spinal muscular atrophy (SMA), phenylketonuria (PKU), Tay-Sachs disease, and various metabolic or mitochondrial syndromes. These conditions may impact growth, neurological function, metabolic pathways, or immune responses, often with severe and irreversible consequences if not identified and treated promptly.

One of the primary challenges in diagnosing these disorders is their heterogeneity. The symptoms of many rare genetic conditions overlap with more common neonatal health issues or remain subtle in the early stages. Some disorders may

present with nonspecific symptoms such as feeding difficulties, poor weight gain, lethargy, or developmental delays—issues often attributed to benign causes unless genetic testing is pursued. This diagnostic ambiguity can delay identification, preventing timely interventions that could mitigate or even prevent the progression of disease [7-11].

Compounding the diagnostic difficulty is the fact that many rare genetic disorders are not included in standard newborn screening panels. Although many countries have established protocols for screening treatable conditions like PKU or congenital hypothyroidism, these panels are limited in scope and often fail to detect less common or newly discovered disorders. Additionally, the current diagnostic process often requires multiple consultations, extensive testing, and the integration of clinical and family history—all of which can delay definitive diagnoses and appropriate care.

Artificial Intelligence presents an opportunity to overcome many of these barriers. By analyzing genomic data alongside clinical observations and medical histories, AI can help pinpoint rare disorders earlier and more accurately than traditional diagnostic methods. As genomic databases grow and algorithms become more refined, AI tools will increasingly enable personalized, predictive, and preventative neonatal care. Understanding the clinical and biological complexity of rare genetic disorders is the first step toward developing AI solutions that can identify and respond to these critical health conditions early in life [12-15].

3. Current Diagnostic Approaches and Limitations

Diagnosing rare genetic disorders in neonates traditionally relies on a combination of biochemical screening, clinical evaluation, family history analysis, and increasingly, genomic sequencing. Standard newborn screening programs typically use blood spot tests collected within days after birth to detect a limited number of treatable conditions. These tests are highly effective for identifying specific disorders like phenylketonuria (PKU) and congenital hypothyroidism but fail to cover the broad spectrum of rare genetic diseases that may present in early infancy. As a result, many conditions go undiagnosed until symptoms become severe or irreversible damage has occurred.

As the medical field has evolved, genetic testing techniques such as chromosomal microarrays, whole exome sequencing (WES), and whole genome sequencing (WGS) have become more accessible. These tools enable clinicians to investigate suspected genetic abnormalities with greater precision. However, these technologies are not without limitations. Turnaround time for results can range from days to several weeks, which is problematic in acute clinical scenarios. In addition, interpreting complex genetic data requires a high degree of expertise and often involves subjective clinical judgment, especially when dealing with variants of uncertain significance [16-19].

Moreover, current diagnostic workflows are fragmented. Patient data may be siloed across multiple healthcare systems, making it difficult to synthesize information from lab results, imaging studies, family history, and clinical notes. The integration of these disparate data streams is crucial for effective diagnosis, yet few systems possess the infrastructure or interoperability required for such a comprehensive approach. This lack of data integration hinders clinicians' ability to connect clinical presentations with underlying genetic causes in a timely and efficient manner.

4. Role of AI in Genomic and Phenotypic Data Analysis

Artificial Intelligence (AI) is revolutionizing the way large-scale biomedical data is analyzed, enabling the detection of patterns and correlations that are often beyond human cognitive capacity. In the context of neonatal rare genetic disorders, AI algorithms, particularly machine learning (ML) and deep learning (DL) models, can process complex genomic data, transcriptomic profiles, and detailed phenotypic information from electronic health records (EHRs) to assist in early diagnosis.

Genomic data analysis using AI involves training models on vast datasets that include known pathogenic variants and their phenotypic consequences. AI tools can identify subtle genotype-phenotype correlations by learning from both labeled data (known cases) and unlabeled data (undiagnosed cases), improving prediction accuracy for rare disorders. Deep learning networks, such as convolutional neural networks (CNNs), have been applied to recognize patterns in genetic sequences that might suggest deleterious mutations or structural variants [20-25].

Beyond genomics, AI integrates phenotypic data — clinical observations, imaging data, and laboratory findings — to build comprehensive diagnostic models. Natural language processing (NLP) techniques can extract relevant clinical signs from unstructured physician notes, enabling the inclusion of detailed clinical context into predictive algorithms. This integration helps to refine differential diagnoses, especially when clinical presentations are ambiguous or overlapping.

5. Integrating AI with Neonatal Screening Programs

Integrating AI into neonatal screening programs offers the potential to enhance the sensitivity, specificity, and efficiency of early genetic disorder detection. Traditional newborn screening involves testing blood samples for a small panel of metabolic and genetic conditions, but the use of AI can expand this scope by analyzing broader genomic data and clinical parameters concurrently.

AI-enhanced workflows can automate the processing of newborn blood spots and genomic sequencing data, flagging high-risk cases for further confirmatory testing. For example, machine learning algorithms can analyze biochemical markers alongside genetic variants to detect subtle abnormalities indicative of rare diseases that may otherwise be missed by conventional screening [26-29].

Pilot programs employing AI-driven tools have demonstrated improved diagnostic yields and faster turnaround times. AI can also prioritize patients by risk stratification, ensuring that neonates with the highest probability of disease receive urgent attention. This triaging helps optimize resource allocation in clinical laboratories and genetic counseling services. Furthermore, AI systems can continuously learn and update screening criteria based on emerging data, enabling adaptive screening panels that evolve with advances in genomic medicine. Integration with hospital EHRs allows seamless data sharing and facilitates longitudinal monitoring of at-risk infants.

Implementing AI in neonatal screening also poses challenges, including the need for standardized data formats, interoperability across healthcare systems, and robust validation to ensure accuracy and safety. Ethical considerations, such as informed consent and data privacy, are paramount when dealing with sensitive genetic information. Overall, the integration of AI with neonatal screening promises a proactive, scalable approach to identifying rare genetic disorders early, potentially preventing severe morbidity and improving long-term outcomes [30-36].

6. Case Studies and Real-World Applications

Several AI-powered platforms have already demonstrated success in the early identification of rare genetic disorders in clinical settings. Tools like Face2Gene and DeepGestalt utilize AI-driven facial analysis to detect subtle dysmorphic features associated with genetic syndromes, facilitating earlier suspicion and testing. These platforms analyze facial photographs using deep convolutional neural networks trained on thousands of images, providing clinicians with diagnostic suggestions that might otherwise be overlooked.

In genomics, AI algorithms have been employed to prioritize variants identified in sequencing data, enabling faster turnaround in diagnosing conditions such as spinal muscular atrophy and cystic fibrosis in neonates. For instance, AI-assisted whole genome sequencing has reduced diagnosis times from months to days in some cases [37-40].

Integration with electronic health records (EHRs) has allowed continuous updating of clinical and genetic data, enabling dynamic patient risk profiling. One example includes AI models that analyze neonatal metabolic screening results combined with clinical parameters to improve detection accuracy of metabolic disorders. Real-world applications also extend to low-resource settings, where AI-powered telemedicine platforms assist clinicians in remotely diagnosing rare diseases. These tools mitigate the shortage of genetic specialists and support global health equity by broadening access to advanced diagnostics.

7. Benefits of AI-Driven Early Detection

The benefits of AI-driven early detection of rare genetic disorders in neonates are profound and multifaceted. Foremost, AI enables significantly faster diagnoses by rapidly analyzing complex data, which is critical in time-sensitive cases where early intervention can prevent irreversible damage or death. Early identification allows for the timely initiation of therapies such as enzyme replacement, gene therapy, or dietary modifications, which can improve developmental outcomes and quality of life. Additionally, AI reduces the so-called “diagnostic odyssey” faced by many families—a prolonged and often distressing journey involving numerous tests, specialists, and uncertainty. By providing more accurate, early diagnoses, AI can alleviate emotional stress and enable families to make informed healthcare decisions sooner. From a healthcare system perspective, early diagnosis through AI can reduce costs by minimizing unnecessary testing, hospitalizations, and ineffective treatments. It also supports precision medicine by tailoring interventions to the patient’s specific genetic profile, potentially enhancing treatment efficacy [41-44].

8. Challenges and Ethical Considerations

Despite its promise, AI-driven early detection raises several challenges and ethical considerations. Data privacy is a foremost concern, as genomic and health data are highly sensitive. Ensuring informed consent, secure data storage, and compliance with regulations such as GDPR and HIPAA is essential to protect patients and families. Algorithmic bias represents another challenge; if training datasets lack diversity, AI tools may perform poorly in underrepresented

populations, exacerbating health inequities. Rigorous validation across diverse cohorts is required to mitigate this risk. There are also concerns about the psychological impact of early genetic diagnoses on families, including anxiety and potential stigma. Genetic counseling must accompany AI-based screening to support families emotionally and help interpret results [45-48].

Reliability and clinical validity of AI models are critical; inaccurate predictions could lead to misdiagnosis or unnecessary interventions. Therefore, continuous monitoring, transparent reporting, and regulatory oversight are imperative to maintain safety. Finally, ethical debates about the scope of newborn screening—such as whether to screen for untreatable conditions or adult-onset diseases—remain unresolved. Clear guidelines balancing benefits and risks are needed as AI expands diagnostic capabilities [49-51].

9. Future Outlook

The future of AI in neonatal rare disease detection is highly promising. Advances in AI algorithms, combined with the exponential growth of genomic and clinical data, will enhance diagnostic accuracy and broaden the range of detectable conditions. Integration with telehealth and wearable health technologies will allow real-time monitoring and early intervention beyond the neonatal period.

Research efforts are underway to develop federated learning approaches that enable AI models to train on decentralized, privacy-preserving datasets, enhancing global collaboration without compromising patient confidentiality. AI is also poised to aid in therapeutic development by identifying novel genetic targets and predicting treatment responses, accelerating personalized medicine.

As AI becomes more embedded in clinical workflows, multidisciplinary collaborations among clinicians, geneticists, data scientists, ethicists, and policymakers will be crucial to address challenges and ensure equitable access. Ultimately, AI-driven early detection could transform neonatal care from reactive to proactive, improving survival and quality of life for countless children worldwide [48-53].

10. Conclusion

AI-driven early detection of rare genetic disorders in neonates represents a transformative leap forward in pediatric healthcare. By harnessing the power of machine learning and deep data integration, AI offers unprecedented opportunities for timely and accurate diagnosis, personalized treatment, and improved outcomes. While significant challenges remain—including data privacy, algorithmic fairness, ethical dilemmas, and the need for rigorous validation—the potential benefits are immense. Early identification not only mitigates lifelong disabilities but also alleviates the emotional and financial burdens on families and healthcare systems.

The integration of AI into neonatal screening programs, combined with ongoing technological and clinical advancements, heralds a new era of precision neonatal medicine. It is imperative that this progress be guided by ethical principles, inclusive data practices, and robust regulatory frameworks to ensure safe, equitable, and effective deployment. In conclusion, AI has the power to revolutionize how rare genetic disorders are detected and managed in neonates, ultimately improving survival rates and quality of life for the most vulnerable patients.

Reference

1. Mostafa, M.A., Soliman, D.A., Behairy, O.G., Abdelgwad, N.M., & Ghanem, A.M. (2024). Preliminary Results of Neonatal Screening of 19 Genetic and Metabolic Disorders in Qalyubia Governorate. *The Egyptian Journal of Hospital Medicine*.
2. Yang, R., Qian, G., Wu, D., Miao, J., Yang, X., Wu, B., Yan, Y., Li, H., Mao, X., He, J., Shen, H., Zou, H., Xue, S., Li, X., Niu, T., Xiao, R., & Zhao, Z. (2023). A multicenter prospective study of next-generation sequencing-based newborn screening for monogenic genetic diseases in China. *World Journal of Pediatrics, 19*, 663 - 673.
3. Pindi, V. (2018). NATURAL LANGUAGE PROCESSING (NLP) APPLICATIONS IN HEALTHCARE: EXTRACTING VALUABLE INSIGHTS FROM UNSTRUCTURED MEDICAL DATA. International Journal of Innovations in Engineering Research and Technology, 5(3), 1-10.
4. Yarlagadda, V. S. T. (2019). AI-Enhanced Drug Discovery: Accelerating the Development of Targeted Therapies. International Scientific Journal for Research, 1(1).
5. Kolla, Venkata Ravi Kiran. (2021). A Secure Artificial Intelligence Agriculture Monitoring System. JournalNX, 2021. Available at SSRN: https://ssrn.com/abstract=4413466
6. Davuluri, M. (2021). AI for Chronic Disease Management: Improving Long-Term Patient Outcomes. International Journal of Machine Learning and Artificial Intelligence, 2(2).
7. Yarlagadda, V. S. T. (2020). AI and Machine Learning for Optimizing Healthcare Resource

Allocation in Crisis Situations. International Transactions in Machine Learning, 2(2).
8. Kolluri, V. (2021). A COMPREHENSIVE STUDY ON AIPOWERED DRUG DISCOVERY: RAPID DEVELOPMENT OF PHARMACEUTICAL RESEARCH. International Journal of Emerging Technologies and Innovative Research (www. jetir. org| UGC and issn Approved), ISSN, 2349-5162.
9. PINDI, V. (2022). ETHICAL CONSIDERATIONS AND REGULATORY COMPLIANCE IN IMPLEMENTING AI SOLUTIONS FOR HEALTHCARE APPLICATIONS. IEJRD-International Multidisciplinary Journal, 5(5), 11.
10. Gatla, T. R. (2024). An innovative study exploring revolutionizing healthcare with ai: personalized medicine: predictive diagnostic techniques and individualized treatment. International Journal of Advanced Research and Interdisciplinary Scientific Endeavours, 1(2), 61-70.
11. Davuluri, M. (2022). Comparative Study of Machine Learning Algorithms in Predicting Diabetes Onset Using Electronic Health Records. Research-gate Journal, 8(8).
12. Kolla, V. R. K. (2023). Exploring the current landscape of artificial intelligence in healthcare. International Journal of Sustainable Development in Computing Science, 1(1).
13. Yarlagadda, V. S. T. (2024). Machine Learning for Predicting Mental Health Disorders: A Data-Driven Approach to Early Intervention. International Journal of Sustainable Development in Computing Science, 6(4).
14. Kolla, Venkata Ravi Kiran. (2020). Forecasting the Future of Cryptocurrency: A Machine Learning Approach for Price Prediction. International Research Journal of Mathematics, Engineering and IT, Volume 7, Issue 12, December 2020. Available at SSRN: https://ssrn.com/abstract=4413732
15. Yarlagadda, V. S. T. (2018). AI for Healthcare Fraud Detection: Leveraging Machine Learning to Combat Billing and Insurance Fraud. Transactions on Recent Developments in Artificial Intelligence and Machine Learning, 10(10).
16. Gatla, T. R. MACHINE LEARNING IN DETECTING MONEY LAUNDERING ACTIVITIES: INVESTIGATING THE USE OF MACHINE LEARNING ALGORITHMS IN IDENTIFYING AND PREVENTING MONEY LAUNDERING SCHEMES (Vol. 6, No. 7, pp. 4-8). TIJER–TIJER–INTERNATIONAL RESEARCH JOURNAL (www. TIJER. org), ISSN: 2349-9249.
17. Kolla, Venkata Ravi Kiran. (2015). Heart Disease Diagnosis Using Machine Learning Techniques in Python: A Comparative Study of Classification Algorithms for Predictive Modeling. International Journal of Electronics and Communication Engineering & Technology, 2015. Available at SSRN: https://ssrn.com/abstract=4413723
18. Yarlagadda, V. S. T. (2021). AI-Driven Early Warning Systems for Critical Care Units: Enhancing Patient Safety. International Journal of Sustainable Development in Computer Science Engineering, 8(8).
19. Gatla, T. R. (2017). A SYSTEMATIC REVIEW OF PRESERVING PRIVACY IN FEDERATED LEARNING: A REFLECTIVE REPORT-A COMPREHENSIVE ANALYSIS. IEJRD-International Multidisciplinary Journal, 2(6), 8.
20. Davuluri, M. (2021). AI in Personalized Oncology: Revolutionizing Cancer Care. International Machine Learning Journal and Computer Engineering, 4(4).
21. Kolla, V. R. K. (2021). Prediction in Stock Market using AI. Transactions on Latest Trends in Health Sector, 13, 13.
22. KOLLURI, V. PATIENT MONITORING WITH AI: CHRONIC DISEASE MANAGEMENT ENHANCEMENTS.
23. Gatla, T. R. (2024). A Groundbreaking Research in Breaking Language Barriers: NLP And Linguistics Development. International Journal of Advanced Research and Interdisciplinary Scientific Endeavours, 1(1), 1-7.
24. Davuluri, M. (2020). AI in Pediatric Healthcare: Transforming Care for Younger Patients. International Numeric Journal of Machine Learning and Robots, 4(4).
25. Kolluri, V. (2016). An Innovative Study Exploring Revolutionizing Healthcare with AI: Personalized Medicine: Predictive Diagnostic Techniques and Individualized Treatment. International Journal of Emerging Technologies and Innovative Research (www. jetir. org| UGC and issn Approved), ISSN, 2349-5162.
26. Kolla, V. R. K. (2023). The Future of IT: Harnessing the Power of Artificial Intelligence. International Journal of Sustainable Development in Computing Science, 5(1).
27. Yarlagadda, V. S. T. (2019). AI for Remote Patient Monitoring: Improving Chronic Disease Management and Preventive Care. International Transactions in Artificial Intelligence, 3(3).
28. MONITORING, R. T. PREDICTION OF PATIENT OUTCOMES USING AI ALGORITHMS.

VEERAVARAPRASAD PINDI. 2018. IJIRCT, Volume 4, Issue 1. Pages 1-14.
29. Gatla, T. R. (2019). A cutting-edge research on AI combating climate change: innovations and its impacts. INNOVATIONS, 6(09).
30. KOLLURI, V. (2024). THE IMPACT OF MACHINE LEARNING ON PATIENT DIAGNOSIS ACCURACY: INVESTIGATING.
31. Yarlagadda, V. S. T. (2017). AI-Driven Personalized Health Monitoring: Enhancing Preventive Healthcare with Wearable Devices. International Transactions in Artificial Intelligence, 1(1).
32. Pindi, V. (2019). A AI-ASSISTED CLINICAL DECISION SUPPORT SYSTEMS: ENHANCING DIAGNOSTIC ACCURACY AND TREATMENT RECOMMENDATIONS. International Journal of Innovations in Engineering Research and Technology, 6(10), 1-10.
33. TOOLS, A. D. D. REVOLUTIONIZING EARLY DETECTION OF DISEASES IN HEALTHCARE. VEERAVARAPRASAD PINDI. 2015. IJIRCT, Volume 1, Issue 1. Pages 1-8.
34. Kolla, V. R. K. (2020). India's Experience with ICT in the Health Sector. Transactions on Latest Trends in Health Sector, 12, 12.
35. Davuluri, M. (2022). AI in Mental Health: Transforming Diagnosis and Therapy. International Machine Learning Journal and Computer Engineering, 5(5).
36. Kolla, Venkata Ravi Kiran. (2021). Cyber security operations centre ML framework for the needs of the users. International Journal of Machine Learning for Sustainable Development, 3(3), 11-20.
37. Yarlagadda, V. (2017). AI in Precision Oncology: Enhancing Cancer Treatment Through Predictive Modeling and Data Integration. Transactions on Latest Trends in Health Sector, 9(9).
38. Davuluri, M. (2020). AI-Driven Drug Discovery: Accelerating the Path to New Treatments. International Journal of Machine Learning and Artificial Intelligence, 1(1).
39. Kolluri, V. (2016). Machine Learning in Managing Healthcare Supply Chains: How Machine Learning Optimizes Supply Chains, Ensuring the Timely Availability of Medical Supplies. International Journal of Emerging Technologies and Innovative Research (www. jetir. org), ISSN, 2349-5162.
40. Yarlagadda, V. S. T. (2018). AI-Powered Virtual Health Assistants: Transforming Patient Care and Healthcare Delivery. International Journal of Sustainable Development in Computer Science Engineering, 4(4).
41. Gatla, T. R. (2018). An explorative study into quantum machine learning: analyzing the power of algorithms in quantum computing. International Journal of Emerging Technologies and Innovative Research (www. jetir. org), ISSN, 2349-5162.
42. Meenigea, N., & Kolla, V. R. K. (2023). Exploring the current landscape of artificial intelligence in healthcare. International Journal of Sustainable Development in Computing Science, 1(1).
43. Yarlagadda, V. S. T., & Davuluri, M. (2024). Novel device for enhancing tuberculosis diagnosis for faster, more accurate screening results. International Journal of Innovations in Engineering Research and Technology, 11(11), 1-15.
44. TOOLS, A. D. D. REVOLUTIONIZING EARLY DETECTION OF DISEASES IN HEALTHCARE. VEERAVARAPRASAD PINDI. 2015. IJIRCT, Volume 1, Issue 1. Pages 1-8.
45. Gatla, T. R. (2018). Enhancing Customer Service In Banks With Ai Chatbots: The Effectiveness And Challenges Of Using Ai-Powered Chatbots For Customer Service In The Banking Sector. TIJER–TIJER–INTERNATIONAL RESEARCH JOURNAL (www. TIJER. org), ISSN, 2349-9249.
46. Hagemeijer, M.C., Oussoren, E., Ruijter, G.J., Onkenhout, W., Huidekoper, H.H., Ebberink, M.S., Waterham, H.R., Ferdinandusse, S., De Vries, M.C., Huigen, M.C., Kluijtmans, L.A., Coene, K.L., & Blom, H.J. (2021). Abnormal VLCADD newborn screening resembling MADD in four neonates with decreased riboflavin levels and VLCAD activity. *JIMD Reports, 61*, 12 - 18.
47. Khalaf, S.M., El-Tellawy, M.M., Refat, N.H., & El-Aal, A.M. (2019). Detection of some metabolic disorders in suspected neonates admitted at Assiut University Children Hospital. *Egyptian Journal of Medical Human Genetics, 20*.
48. Thatoi, P., Choudhary, R., Mukeshkumar, P.D., Selvarathinam, A.L., & Swapnil Rout, S. (2024). Transforming Rheumatoid Arthritis Management: Harnessing Artificial Intelligence for Early Detection, Personalized Treatment, and Ethical Challenges. *International Journal of Research and Innovation in Applied Science*.
49. Awaji, B.M., Senan, E.M., Olayah, F., Alshari, E.A., Alsulami, M., Abosaq, H.A., Alqahtani, J., & Janrao, P. (2023). Hybrid Techniques of Facial Feature Image Analysis for Early Detection of Autism Spectrum Disorder Based on Combined CNN Features. *Diagnostics, 13*.
50. Jha, R.K., Kaple, M.N., Ambad, R.S., Dhok, A.J., & Anjankar, A. (2024). Comprehensive Neonatal

Screening for Genetic Disorders in Tribal Populations of Central India. *Journal of Pharmacy & Bioallied Sciences, 16*, S4021 - S4025.

51. Nawghare, P., & Prasad, J.R. (2024). Early Detection of Autism Spectrum Disorder Using AI and Machine Learning Models: A Systematic Review for Effective Intervention. *2024 IEEE Pune Section International Conference (PuneCon)*, 1-6.
52. Gopalakrishnan, R., Pg, V., S, S., & W, L.J. (2025). Early Detection and Management of Glucose-6-Phosphate Dehydrogenase Deficiency through Newborn Screening: A Case Study and Public Health Perspective. *Asian Journal of Biochemistry, Genetics and Molecular Biology*.
53. Salarian, L., Ilkhanipoor, H., Amirhakimi, A., Afshar, Z., Nahid, S., Moradi Ardekani, F., Rahimi, N., Yazdani, N., Nikravesh, A., Beyzaei, Z., & Moravej, H. (2025). Epidemiology of inherited metabolic disorders in newborn screening: insights from three years of experience in Southern Iran. *Orphanet Journal of Rare Diseases, 20*.